[EN] FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY [FR] DÉRIVÉS DE [1,2,4]THIADIAZINE FUSIONNÉS AGISSANT EN TANT QU'INHIBITEURS DE KAT DE LA FAMILLE DES MYST
[EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
申请人:CALICO LIFE SCIENCES LLC
公开号:WO2020186199A1
公开(公告)日:2020-09-17
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
[EN] UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS<br/>[FR] DÉRIVÉS D'URÉE UTILISÉE EN TANT QUE MODULATEURS ALLOSTÉRIQUES DE CB1
申请人:RTI INT
公开号:WO2020264176A1
公开(公告)日:2020-12-30
Heteroaryl and aliphatic analogs of diarylurea-based cannabinoid 1 receptor (CB1 R) allosteric modulators of formula (I) are described. Exemplary analogs can provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1 R, such as substance abuse and obesity are described.
[EN] N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS<br/>[FR] DÉRIVÉS DE N-HÉTÉROARYLALKYLE-2-(HÉTÉROCYCLYLE ET HÉTÉROCYCLYLMÉTHYLE) ACÉTAMIDE UTILISÉS EN TANT QU'AGONISTES DE SSTR4
申请人:TAKEDA PHARMACEUTICALS CO
公开号:WO2021202781A1
公开(公告)日:2021-10-07
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.
Three-component synthesis of fluorinated pyrazoles from fluoroalkylamines, NaNO<sub>2</sub> and electron-deficient alkynes
作者:Pavel K. Mykhailiuk
DOI:10.1039/c4ob02670e
日期:——
Three-component reaction between RCF2CH2NH2.HCl, NaNO2 and electron-deficient alkynes significantly depends on substituent "R". The reaction gives the fluorinated pyrazoles in high yields when "R" is a fluorine atom or a fluoroalkyl group. With other "R" unexpected products are formed.
[EN] MASP-2 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MASP-2 ET PROCÉDÉS D'UTILISATION
申请人:OMEROS CORP
公开号:WO2021113686A1
公开(公告)日:2021-06-10
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.